Depuydt, Marie A. C.
Vlaswinkel, Femke D.
Hemme, Esmeralda
Delfos, Lucie
Kleijn, Mireia N. A. Bernabé
van Santbrink, Peter J.
Foks, Amanda C.
Slütter, Bram
Kuiper, Johan
Bot, Ilze
Funding for this research was provided by:
Hartstichting (CVON2017-20: Generating the best evidence-based pharmaceutical targets and drugs for atherosclerosis (GENIUS II), 2019T067, 2019T067, 2018T051, CVON2017-20: Generating the best evidence-based pharmaceutical targets and drugs for atherosclerosis (GENIUS II), CVON2017-20: Generating the best evidence-based pharmaceutical targets and drugs for atherosclerosis (GENIUS II), CVON2017-20: Generating the best evidence-based pharmaceutical targets and drugs for atherosclerosis (GENIUS II))
NWO-ZonMW (PTO program: 95105013, PTO program: 95105013, PTO program: 95105013)
Article History
Received: 20 June 2022
Accepted: 26 October 2022
First Online: 1 November 2022
Competing interests
: The authors declare no competing interests.